Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tiagin is a vaginal topical treatment formulated as softgel capsules containing **TIAB** (a patented complex of microcrystalline titanium dioxide and covalently linked monovalent silver ions), sodium hyaluronate, and *Aloe barbadensis* extract. It is primarily utilized as an adjuvant therapy to prevent postoperative complications following gynecological surgeries, such as total hysterectomy or cervical conization, and to manage vaginal infections including those caused by bacteria, fungi, and viruses (e.g., HPV). The TIAB component functions as a broad-spectrum antimicrobial by releasing silver ions that disrupt microbial membranes and DNA while also preventing the formation of pathogenic biofilms. The addition of sodium hyaluronate and aloe extract facilitates tissue repair and re-epithelialization by maintaining a hydrated environment and stimulating collagen production and modeling.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Tiagin.